Lukas C. Amler,Merrill Birkner,Chin-Yu Lin,Joachim Moecks,Andreas Strauss
申请号：
US13648085
公开号：
US08940302B2
申请日:
2012.10.09
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab.It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab.In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
